Implementation of TMA and digitalization in routine diagnostics of breast pathology
暂无分享,去创建一个
A. Lænkholm | M. Talman | Henrik Holm Rossing | Maj‐Lis Møller Talman | Anne‐Vibeke Lænkholm | Vera Timmermans Wielenga | H. H. Rossing | V. T. Wielenga
[1] S. Lakhani,et al. Aberrant Expression of E-cadherin in Lobular Carcinomas of the Breast , 2008, The American journal of surgical pathology.
[2] G. Divine,et al. E-cadherin status in breast cancer correlates with histologic type but does not correlate with established prognostic parameters. , 2006, American journal of clinical pathology.
[3] W. McGuire,et al. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. , 1987, Science.
[4] Jens Overgaard,et al. retrospective analysis of topoisomerase IIa amplifications and deletions as predictive markers in primary breast cancer patients randomly assigned to cyclophosphamide, methotrexate, and fluorouracil or cyclophosphamide, epirubicin, and fluorouracil: Danish Breast Cancer Cooperative Group. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[5] P. Ellis,et al. Adjuvant trastuzumab for HER2-positive breast cancer , 2005, The Lancet.
[6] P. Neven,et al. Prognostic and predictive value of centrally reviewed expression of estrogen and progesterone receptors in a randomized trial comparing letrozole and tamoxifen adjuvant therapy for postmenopausal early breast cancer: BIG 1-98. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[7] Charles M. Perou,et al. Ki67 Index, HER2 Status, and Prognosis of Patients With Luminal B Breast Cancer , 2009, Journal of the National Cancer Institute.
[8] R Peto,et al. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.
[9] Anthony Rhodes,et al. American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. , 2006, Archives of pathology & laboratory medicine.
[10] N. Sneige,et al. HER-2/neu gene amplification compared with HER-2/neu protein overexpression and interobserver reproducibility in invasive breast carcinoma. , 2000, American journal of clinical pathology.
[11] R. Gelber,et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. , 2011, The Lancet. Oncology.
[12] A. Fabi,et al. Improved prognosis by trastuzumab of women with HER2-positive breast cancer compared with those with HER2-negative disease. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[13] M. Cotreau,et al. Phase I study of SCH 900105 (SC), an anti-hepatocyte growth factor (HGF) monoclonal antibody (MAb), as a single agent and in combination with erlotinib (E) in patients (pts) with advanced solid tumors. , 2010 .
[14] F. B. Sørensen,et al. Tissue microarrays compared with whole sections and biochemical analyses. A subgroup analysis of DBCG 82 b&c. , 2008, Acta oncologica.
[15] C. Desmedt,et al. Final results of a meta-analysis testing HER2 and topoisomerase IIα genes as predictors of incremental benefit from anthracyclines in breast cancer. , 2010 .
[16] J. Winston,et al. HER-2/neu evaluation in breast cancer are we there yet? , 2004, American journal of clinical pathology.
[17] H. Mouridsen,et al. [Danish Breast Cancer Cooperative Group]. , 2012, Ugeskrift for laeger.
[18] J. Kononen,et al. Tissue microarrays for high-throughput molecular profiling of tumor specimens , 1998, Nature Medicine.
[19] R. Gelber,et al. Meeting highlights: international expert consensus on the primary therapy of early breast cancer 2005. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.
[20] B. Rasmussen,et al. Semi-quantitative scoring of potentially predictive markers for endocrine treatment of breast cancer: a comparison between whole sections and tissue microarrays , 2006, Journal of Clinical Pathology.
[22] Early Breast Cancer Trialists' Collaborative Group. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: patient-level meta-analysis of randomised trials , 2011, The Lancet.